Oral mucositis has been identified as the most debilitating side effect of anticancer therapy by patients who experienced it while undergoing myelotoxic therapy for Hematopoietic Stem Cell Transplantation (HSCT)1,2

Help build in cellular protection against severe oral mucositis with Kepivance®

Kepivance® is a recombinant protein that mimics the activity of endogenous keratinocyte growth factor (KGF).3 Kepivance® binds to the KGF receptor on the cell surface, the receptor responsible for stimulating epithelial cell proliferation, differentiation, and migration in addition to upregulating cytoprotective mechanisms.3-7

Kepivance® has been shown to3,8 :

  • reduce the duration of oral mucositis
  • reduce the duration of Grade 3/4 oral mucositis by 33%
  • decrease the incidence of severe oral mucositis

Kepivance® patients reported significantly less mouth and throat soreness and significantly less functional decline in eating, drinking, swallowing, and talking.3,8

References

1. Bellm LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000;8:33-39.
2. Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant. 2001;27(suppl 2):S3-S11.
3. Kepivance® (palifermin) prescribing information, Amgen.
4. Danilenko DM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol. 1999;27:64-71.
5. Werner S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine & Growth Factor Reviews. 1998;9:153-165.
6. Farrell CL, Rex KL, Chen JN, et al. The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif. 2002;35(suppl 1):78-85.
7. Jonas CR, Farrell CL, Scully S, et al. Enteral nutrition and keratinocyte growth factor regulate expression of glutathione-related enzyme messenger RNAs in rat intestine. J Parenter Enteral Nutr. 2000;24:67-75.
8. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590-2598.